More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.02B
EPS
0.77
P/E ratio
14.8
Price to sales
4.53
Dividend yield
--
Beta
0.651084
Previous close
$13.47
Today's open
$13.34
Day's range
$13.12 - $13.66
52 week range
$7.21 - $20.46
show more
CEO
Adam S. Grossman
Employees
647
Headquarters
Ramsey, NJ
Exchange
NASDAQ Global Market
Shares outstanding
221854389
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Here's Why Adma Biologics (ADMA) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research • Nov 13, 2026

ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?
ADMA Biologics gains 20.9% after strong Q3 results, as surging Asceniv sales and a raised 2026 profit outlook offset Bivigam weakness and competitive pressures.
Zacks Investment Research • Nov 11, 2026

Why Adma Biologics (ADMA) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research • Nov 11, 2026

Adma Biologics (ADMA) Recently Broke Out Above the 200-Day Moving Average
From a technical perspective, Adma Biologics (ADMA) is looking like an interesting pick, as it just reached a key level of support. ADMA recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
Zacks Investment Research • Nov 6, 2026

Adma Biologics (ADMA) Just Overtook the 20-Day Moving Average
After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
Zacks Investment Research • Nov 6, 2026

ADMA Biologics, Inc. (ADMA) Q3 2026 Earnings Call Transcript
ADMA Biologics, Inc. (ADMA) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 5, 2026

ADMA Biologics Q3 Earnings Call Highlights
ADMA Biologics NASDAQ: ADMA raised its minimum full-year earnings expectations after third-quarter profit rose on stronger sales of ASCENIV and improved manufacturing yields, even as competitive pressure weighed on its BIVIGAM product.
MarketBeat • Nov 4, 2026

ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update
3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year 3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year 3Q 2026 GAAP Net Income of $49.9 Million, Increasing 37% Year-over-Year 3Q 2026 Adjusted Net Income ( 1) of $51.1 Million, Increasing 31% Year-over-Year 3Q 2026 GAAP Basic EPS of $0.22, Increasing 47% Year-over-Year 3Q 2026 Adjusted Basic EPS ( 2) of $0.23, Increasing 44% Year-over-Year 3Q 2026 Adjusted EBITDA ( 3 ) of $77.3 Million, Increasing 32% Year-over-Year 3Q 2026 Gross Margin of 71%, Expanding Approximately 1,450 Basis Points Year-over-Year Expanding ASCENIV Real-World Health Outcomes Evidence Strengthens Commercial Differentiation Robust Cash Generation, Operating Leverage and Share Repurchases Support Stockholder Value Encouraging Regulatory Feedback Received from SG-001 Pre-IND Meeting Package Reiterates FY2026 Revenue Guidance; Increases Adjusted Earnings Outlook RAMSEY, N.J. and BOCA RATON, Fla.
GlobeNewsWire • Nov 4, 2026

Adma Biologics (ADMA) Q3 Earnings and Revenues Beat Estimates
Adma Biologics (ADMA) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $11.41, denoting a -2.89% move from the preceding trading day.
Zacks Investment Research • Oct 30, 2026

¹ Disclosures

Open an M1 investment account to buy and sell ADMA Biologics Inc commission-free¹. Build wealth for the long term using automated trading and transfers.